Skip to main content
. 2019 Feb 19;93(5):e01783-18. doi: 10.1128/JVI.01783-18

FIG 2.

FIG 2

Level of in vivo CH31 and de novo binding responses in vaccinated macaques. (A) Levels of CH31 MAb in groups that received CH31 coadministration, measured as Env-specific human (hu) IgG. D, day; wk, week. (B) Levels of IgG binding for vaccine strain 1086.C gp120 over time as measured in an anti-monkey IgG ELISA. (C) Magnitude of binding to a panel of HIV-1 Env antigens as measured in BAMA. (D) Magnitude of binding to a panel of region/epitope-specific antigens as measured in BAMA. *, unadjusted P < 0.05; **, unadjusted P < 0.01. All P values are >0.05 once values were adjusted for multiple comparison (Tables 1 S1, and S2 give both unadjusted P and FDR P values for all comparisons). Black horizontal bars represent group median values. For panel D, binding to the V3 Ag panel ($) (calculated as mean MFI for gp70 Con V3, gp70-MN V3, and linear V3.C by each animal) was lower for the Env-only group than for the MVA/Env group at week 2 (unadjusted P < 0.05).